Biocon Biologics partners with Sandoz Australia to sell cancer drugs
.webp)
Biocon Biologics has announced a five-year partnership with Sandoz Australia to market its products Ogivri, (biosimilar Trastuzumab) and Fulphila, (biosimilar Pegfilgrastim) in Australia. Both are cancer products.
This partnership will provide Sandoz the exclusive rights to promote, sell, and distribute biosimilar Trastuzumab and biosimilar Bevacizumab in Australia.
"Following the recent establishment of our strategic partnership with Sandoz in Japan, our agreement with Sandoz in Australia marks another important milestone of our global partnership and growth strategy. This relationship is also a crucial step for patients in Australia, ensuring continued access to high-quality, affordable biosimilar medicines used in oncology,” said Matt Erick, chief commercial officer of Advanced Markets, Biocon Biologics.
Under the agreement, Sandoz will distribute Biocon Biologics’ brands, OGIVRI and ABEVMY (bBevacizumab), and facilitate the sustained access of these medications that were previously distributed by another pharmaceutical company to patients in Australia. Trastuzumab is a biosimilar of Herceptin and Bevacizumab is a biosimilar of Avastin – both biosimilars are available on the PBS and utilised for the treatment of various cancers.
Biocon said that the agreement is effective from January 1, 2024, and commercialisation commenced on February 1, 2024.
Other Latest News
.webp)
Chief Minister Nayab Singh Saini will be meeting the senior BJP leadership in Delhi on Wednesday, a day after the ruling party pulled off a hat-trick of wins in Haryana to retain power.
Saini is likely to consult with his senior leadership on finalising his cabinet, sources said.
.webp)
Boeing said on Tuesday that it had withdrawn its pay offer to around 33,000 US factory workers and no further negotiations were planned with their union representatives as a financially damaging strike nears its fourth week.
Boeing and the union held their latest round of negotiations with federal mediators on Monday and Tuesday, but talks collapsed and the sides were left locked in acrimonious stalemate showing no signs of being resolved anytime soon, a person briefed on the talks said.
.webp)
Torrent Power shares gained 8 per cent in trade on Wednesday, October 9, and registered an intraday high of Rs 1,976.6 per share. The stock advanced after Torrent Power secured a letter of award from Maharashtra State Electricity Distribution (MSEDCL). It also inked a share subscription and shareholders' agreement (SSSA) with Lakshmi Mills and Torrent Urja 17 Private Limited (TU17).
At around 9:22 AM, Torrent Power share price was up 6.85 per cent at Rs 1,941.7 per share. In comparison, the BSE Sensex traded 145.48 per cent higher at 81,780.29 around the same time.
.webp)
Hyundai Motor India's IPO will open next week for subscriptions and will likely be priced in the range of Rs 1,865 to 1,960 ($22 to $23) per share, sources said on Tuesday, valuing the automaker at up to $19 billion in the country's biggest stock offering this year.
The India IPO will be Hyundai's first stock market listing outside South Korea. In India, it will also mark the first carmaker to go public in two decades since Maruti Suzuki in 2003, and comes just after Indian stock markets touched record highs and saw many companies making debuts.
.webp)
In the Jammu and Kashmir Assembly elections, the Bharatiya Janata Party (BJP) secured the highest share of votes, although the Congress-National Conference (NC) alliance ultimately won the polls. This was the first election in J&K following the abrogation of Article 370. The Congress-NC alliance is now set to form the government, having secured a majority of seats in the Assembly.
Notably, Independent candidates won more seats than Mehbooba Mufti’s People’s Democratic Party (PDP).
.webp)
.webp)
.webp)
.webp)
.webp)
